Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 47%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb has demonstrated a significant increase in its probability of success (PoS) for key drugs, such as milvexian and iber/mezi, leading to a robust increase in projected risk-adjusted sales, with estimates rising from $988 million to $1.2 billion for milvexian and from $1.3 billion to $3.6 billion for the combined sales of iber and mezi by 2033. The firm has also received positive guidance ahead of sell-side consensus, alleviating concerns about future performance, especially within its growth products and the anticipated strong sales growth of Eliquis. Additionally, trends in the market and strong physician feedback regarding CELMoDs have sparked investor interest, solidifying confidence in Bristol-Myers Squibb's growth trajectory and strategic direction in transformative therapies.

Bears say

Bristol-Myers Squibb's stock outlook is negatively impacted by a significant delay in the regulatory approval and launch date of a new product, which could detrimentally affect revenues and earnings. The company's forward EV/EBITDA multiple remains below the average of its peers at 11.2x, suggesting potential undervaluation in comparison to industry standards. Furthermore, the firm faces substantial risks in its clinical trials, including possible regulatory approval setbacks and evolving market conditions that could jeopardize the viability of new products or existing enhancements.

Bristol-Myers (BMY) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 47% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 15 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.